GleamWall
中文EN

HCWB HCW Biologics Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1828673 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY1,487.6%
TTM net income YoY64.7%
TTM EPS YoY162.3%
Revenue 3-yr CAGR32.8%
Net income 3-yr CAGR—

Margins

Gross margin96.6%
Operating margin-104.2%
Net margin-63.4%
FCF margin—
EBITDA margin-96.1%

Returns

ROE-180.3%
ROA-16.8%
ROIC (approx.)-116.5%
Asset turnover0.26x

Leverage & solvency

Liabilities / assets72.8%
Debt / equity0.00x
Current ratio0.07x
Interest coverage-12.39x

Cash quality & payout

Operating cash flow / net income2.71x
Accruals ratio28.7%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$51,169$121,730$6.50M$27,010$15,606$6,550$5,065$394,804
Cost of revenue$27,345$229,455$11,071$21,609$12,485$5,240$4,052$315,843
Gross profit$28,118-$93,887$6.53M$5,401$3,121$1,310$1,013$78,961
R&D expense$1.24M$1.20M$1.26M$1.33M$1.40M$1.23M$1.48M$1.05M
SG&A expense$1.37M$1.87M$1.83M$1.51M$1.88M$2.10M$2.23M$2.03M
Operating income-$2.59M-$3.17M$3.24M-$4.46M-$3.29M-$3.46M-$1.97M-$3.15M
Interest expense$141,797$100,541$109,274$212,128$127,070$228,714$255,822$260,376
Pretax income-$3.22M-$5.22M$3.80M$719,232-$4.55M-$1.93M-$2.20M—
Income tax$0$0$330,186$0——$0$0
Net income-$3.22M-$5.22M$3.47M$719,232-$4.55M-$1.93M-$2.20M-$3.37M
EBITDA-$2.47M-$3.04M$3.38M-$4.30M-$3.12M-$3.17M-$1.55M-$2.46M
EPS (basic)-2.83-11.581.39—-12.09-40.72-11.80—
EPS (diluted)-2.83-11.581.39—-12.09-40.72-11.80—
Weighted avg. shares (diluted)2.10M1.33M904,312—376,678296,686186,149—
Balance sheet
Cash & equivalents$955,458$741,324$1.23M$1.95M$1.10M$2.44M$1.11M$4.67M
Short-term investments$0$0$0$0$0$0$0$0
Receivables—$18,451$74,844$32,175$30,667$21,611$87,493$582,201
Current assets$1.28M$1.14M$1.72M$2.28M$1.59M$2.90M$1.89M$5.70M
PP&E, net$18.96M$20.75M$20.77M$20.88M$22.50M$22.64M$22.76M$22.91M
Total assets$25.13M$26.77M$27.34M$24.52M$25.45M$28.91M$26.29M$30.24M
Current liabilities$17.61M$18.65M$19.96M$21.06M$26.86M$26.85M$27.14M$29.63M
Short-term debt$6.83M$6.56M$6.58M$6.81M$6.81M$6.42M$6.23M$6.31M
Long-term debt———$0$0$367,151$7.71M$7.38M
Total debt———$6.81M$6.81M$6.79M$13.94M$13.69M
Total liabilities$18.30M$19.34M$21.58M$21.76M$27.55M$28.96M$34.85M$37.01M
Shareholders' equity$6.82M$7.43M$5.76M$2.76M-$2.11M-$51,971-$8.56M-$6.77M
Net debt———$4.86M$5.71M$4.35M$12.83M$9.02M
Cash flow statement
Operating cash flow-$2.62M-$3.97M-$1.58M-$3.36M-$3.24M-$3.28M-$3.51M-$2.83M
Capital expenditure———$0$0$0$0$113,412
Free cash flow———-$3.36M-$3.24M-$3.28M-$3.51M-$2.95M
Investing cash flow———$0$0$0$0-$113,412
Financing cash flow$2.83M$3.48M$851,641$4.21M$1.90M$4.61M-$53,103$6.62M
Depreciation & amortization$120,072$127,095$142,049$156,940$173,905$291,916$419,010$682,507
Stock-based compensation$364$1,220$10,019$9,182$205,492$278,307$275,642$292,071

Free plan shows the latest 8 periods; Pro shows all 27 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.